Fibroblasts influence survival and therapeutic response in a 3D co-culture model

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Majety, Meher ^a   Pradel, Leon P ^a   Gies, Manuela ^a   Ries, Carola H ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; ONARTUZUMAB; SCATTER FACTOR; CYTOKINE; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CONTACT; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER CELL LINE; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; THREE DIMENSIONAL COCULTURE; TREATMENT RESPONSE; TUMOR ASSOCIATED FIBROBLAST; TUMOR MICROENVIRONMENT; CELL LINE; CYTOLOGY; MULTICELLULAR SPHEROID; PROCEDURES; SECRETION (PROCESS);

CELL LINE; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOKINES; FIBROBLASTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SPHEROIDS, CELLULAR;

EID: 84936768418     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127948     Document Type: Article

References (24)

1. Pietras K, Ostman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Experimental cell research 316: 1324-1331. doi: 10.1016/j.yexcr.2010.02.045 PMID: 20211171
2. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, et al. (2011) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast cancer research and treatment 125: 687-696. doi: 10.1007/s10549-010-0855-6 PMID: 20361254
3. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature medicine 15: 68-74. doi: 10.1038/nm.1908 PMID: 19122658
4. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. (2011) Stromal biology and therapy in pancreatic cancer. Gut 60: 861-868. doi: 10.1136/gut.2010.226092 PMID: 20966025
5. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. (2011) The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and nonsmall cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 6: 209-217.
6. Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiological reviews 76: 69-125. PMID: 8592733
7. Angeli F, Koumakis G, Chen MC, Kumar S, Delinassios JG (2009) Role of stromal fibroblasts in cancer: promoting or impeding? Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 30: 109-120. doi: 10.1159/000218708 PMID: 19440007
8. Mishra P, Banerjee D, Ben-Baruch A (2011) Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. Journal of leukocyte biology 89: 31-39. doi: 10.1189/jlb.0310182 PMID: 20628066
9. Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, et al. (2011) Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PloS one 6: e15313. doi: 10.1371/journal.pone.0015313 PMID: 21249190
10. Micke P, Ostman A (2004) Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung cancer 45 Suppl 2: S163-175. PMID: 15552797
11. Samoszuk M, Tan J, Chorn G (2005) Clonogenic growth of human breast cancer cells co-cultured in direct contact with serum-activated fibroblasts. Breast cancer research: BCR 7: R274-283. PMID: 15987422
12. Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, et al. (2011) Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Molecular cancer research: MCR 9: 3-13. doi: 10.1158/1541-7786.MCR-10-0372 PMID: 21131600
13. Fujita H, Ohuchida K, Mizumoto K, Egami T, Miyoshi K, Moriyama T, et al. (2009) Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer science 100: 2309-2317. doi: 10.1111/j.1349-7006.2009.01317.x PMID: 19735487
14. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. (2009) A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer research 69: 3364-3373. doi: 10.1158/0008-5472.CAN-08-4210 PMID: 19351829
15. Shay JW, Wright WE (2007) Tissue culture as a hostile environment: identifying conditions for breast cancer progression studies. Cancer cell 12: 100-101. PMID: 17692800
16. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, et al. (2011) Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. The American journal of pathology 179: 1483-1493. doi: 10.1016/j.ajpath.2011.05.060 PMID: 21763682
17. Chong CR, Janne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature medicine 19: 1389-1400. doi: 10.1038/nm.3388 PMID: 24202392
18. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer research 55: 2007-2011. PMID: 7743492
19. Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, et al. (2012) Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein engineering, design & selection: PEDS 25: 551-559.
20. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, et al. (2010) Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 16: 174-183.
21. Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, et al. (2008) Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 19: 1605-1612.
22. Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast cancer research and treatment 120: 491-498. doi: 10.1007/s10549-010-0758-6 PMID: 20135347
23. Weidle UH, Klostermann S, Eggle D, Kruger A (2010) Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer genomics & proteomics 7: 287-302.
24. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Molecular cell 47: 570-584. doi: 10.1016/j.molcel.2012.06.014 PMID: 22819326